Published on 21/12/2025
How to Perform Causality Assessment in Adverse Event Reporting for Clinical Trials
Determining whether an adverse event (AE) is related to an investigational product is a core responsibility in clinical trial safety management. This process, called causality assessment, is critical for regulatory compliance, participant safety, and scientific integrity. In this guide, we explore how to perform causality assessments correctly, using structured tools and globally accepted frameworks.
What is Causality Assessment?
Causality assessment is the systematic evaluation of the likelihood that an adverse event (AE) was caused by the investigational product or another factor. This evaluation is essential for classifying AEs, especially when reporting serious adverse events (SAEs) to sponsors and regulatory agencies like USFDA or CDSCO.
Why Causality Assessment is Important:
- Enables accurate drug safety profiling
- Supports safety signal detection and pharmacovigilance
- Guides regulatory submissions and labeling
- Determines reporting timelines and requirements
- Ensures compliance with pharma regulatory compliance standards
Who is Responsible for Causality Assessment?
- Investigator: Makes the initial causality determination, based on clinical judgment and available evidence
- Sponsor: May provide an independent causality assessment for pharmacovigilance purposes
- Regulatory Authorities: Review submitted assessments to determine product safety
Standard Tools for Causality Assessment:
1. WHO-UMC System
This method classifies the relationship into categories:
- Certain
- Probable/Likely
- Possible
- Unlikely
- Conditional/Unclassified
- Unassessable/Unclassifiable
Widely used for spontaneous and clinical trial AE assessment, especially in global trials regulated by the EMA.
2. Naranjo Algorithm
A point-based questionnaire used to assess the likelihood of drug-related adverse reactions. Scores categorize the event as:
- ≥ 9: Definite
- 5–8: Probable
- 1–4: Possible
- 0: Doubtful
3. Clinical Judgment + Protocol Guidance
Some protocols use simplified binary classification (Related / Not Related) or a three-level scale (Related / Possibly Related / Not Related).
How to Perform a Causality Assessment Step-by-Step:
Step 1: Review AE Details
Examine onset, duration, severity, seriousness, clinical signs, lab results, and medical history.
Step 2: Consider Temporal Relationship
Did the AE occur after drug administration? If yes, how soon after? Timing is a critical clue in causality assessment.
Step 3: Exclude Alternative Causes
Was there another plausible explanation such as a co-medication, underlying illness, or external exposure?
Step 4: Check Rechallenge and Dechallenge Outcomes
Did the AE resolve upon discontinuation (dechallenge)? Did it recur after reintroduction (rechallenge)?
Step 5: Review Product Label and Known Risks
Is the event a known or listed side effect per the Investigator’s Brochure or product insert?
For guidance on documentation, refer to SOP compliance pharma procedures and AE reporting templates.
Best Practices for Investigators:
- Use structured causality tools consistently
- Document rationale clearly in source notes and CRF
- Train site staff on criteria for relatedness
- Use standardized terms and avoid vague language (“maybe related”)
- Ensure investigator’s signature on AE and SAE forms
Common Mistakes to Avoid:
- Using “Unknown” or “Not Sure” without justification
- Leaving causality field blank in CRF
- Failing to consider time sequence and product profile
- Inconsistent causality assignment across follow-up visits
Sample Case Scenarios:
Case 1: AE Likely Related
Patient experienced nausea 1 hour after investigational drug administration. Event resolved upon stopping medication. Similar AEs reported in earlier studies.
Causality: Probable (per WHO-UMC) or Score 7 (Naranjo)
Case 2: AE Unrelated
Subject developed fever three weeks after last dose. Blood culture reveals bacterial infection from a non-study source.
Causality: Unlikely
Regulatory Perspective on Causality:
- USFDA: Requires causality assignment by investigator for IND safety reports
- EMA: Sponsors must submit related SAEs and suspected unexpected serious adverse reactions (SUSARs)
- CDSCO: Investigator must assess relatedness and include signed SAE form
How Sponsors Review Causality:
Sponsors may independently assess AE relatedness using safety database algorithms or medical monitors. Discrepancies are documented and may require justification.
Integrating Causality into Study Systems:
- EDC systems should require causality input fields
- CRFs should capture assessment criteria (e.g., timing, outcome)
- CTMS and PV databases should flag related SAEs for expedited reporting
Many tools like those available through StabilityStudies.in include built-in causality assessment checklists, training modules, and validation reports.
Final Checklist for Causality Assessment:
- [ ] AE timing evaluated
- [ ] Alternative causes considered
- [ ] Dechallenge/rechallenge reviewed
- [ ] Product profile reviewed
- [ ] Causality assigned and justified
- [ ] CRF and source records updated
- [ ] Signed by Investigator
Conclusion:
Causality assessment is not guesswork—it’s a structured, evidence-based process. By applying validated tools, documenting consistently, and training investigators thoroughly, clinical teams can ensure accurate AE classifications, promote patient safety, and meet the high standards of global regulatory compliance. Every AE deserves a thoughtful evaluation—because the consequences of misjudgment can ripple across the trial, the product, and ultimately, the patient community.